Targeted oncology · 2025
Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mourlanette Jean, Rousseau-Bussac Gaelle, Mallah Siham, Guisier Florian, Zalcman Gerard, Veillon Rémi, Audigier-Valette Clarisse, Roa Magali, Nicolle Isabelle, Doubre Helene, Cloarec Nicolas, Lamy Régine, Morel Hugues, Curcio Hubert, Lagrange Aurélie, Schott Roland, Sabatini Marielle, Toffart Anne Claire, Pinsolle Julian, Bennouna Jaafar, Chouaid Christos, Mazieres Julien
Аннотация
BACKGROUND: ROS1 chromosomic rearrangement is a rare oncogenic driver, and patients with this rearrangement benefit from specific targeted treatments in the first-line setting. However, therapeutic options are limited in pretreated patients. Brigatinib is a validated drug for ALK rearrangements, and also has an in vitro activity against ROS1. In vivo efficacy is also suggested in some clinical series.
OBJECTIVE: We aimed to specifically study brigatinib in patients with pretreated advanced non-small-cell lung cancer (NSCLC).
METHODS: We retrospectively collected data from 20 centers in France. Brigatinib was delivered through a compassionate use program in France between 2018 and 2020. The primary endpoint was progression-free survival. Secondary endpoints were the objective response rate, overall survival, and tolerance.
RESULTS: Twenty-five patients treated with brigatinib were included in our study. All patients were pretreated, and all of them previously received crizotinib. Median progression-free survival was 3.8 months (95% confidence interval 2.8-7.1). The objective response rate was 32%, with a disease control rate of 48%. Three patients had a prolonged response of more than 18 months at the end of data collection. We did not identify factors predictive of prolonged response. There were no grade 4 or 5 toxicities.
CONCLUSION: Brigatinib may represent an interesting therapeutic option for patients who have progressed after standard treatments.
OBJECTIVE: We aimed to specifically study brigatinib in patients with pretreated advanced non-small-cell lung cancer (NSCLC).
METHODS: We retrospectively collected data from 20 centers in France. Brigatinib was delivered through a compassionate use program in France between 2018 and 2020. The primary endpoint was progression-free survival. Secondary endpoints were the objective response rate, overall survival, and tolerance.
RESULTS: Twenty-five patients treated with brigatinib were included in our study. All patients were pretreated, and all of them previously received crizotinib. Median progression-free survival was 3.8 months (95% confidence interval 2.8-7.1). The objective response rate was 32%, with a disease control rate of 48%. Three patients had a prolonged response of more than 18 months at the end of data collection. We did not identify factors predictive of prolonged response. There were no grade 4 or 5 toxicities.
CONCLUSION: Brigatinib may represent an interesting therapeutic option for patients who have progressed after standard treatments.